About Biocon Biocon's Products & Services Research & Development Biocon's Technology Investors Media Careers CSR
Biocon-Media
     
 

Company Statement

Biocon Regulatory Audit Update

Bengaluru, India, May 02, 2018

"The US-FDA has completed a pre-approval inspection of our sterile drug product manufacturing facility in Bangalore this week and issued a Form 483 with 7 observations. The observations are largely procedural and aimed at continuous improvement. We will respond to the FDA with a corrective and preventive action plan in a timely manner.

We have also this week received the preliminary report from the European Regulator post inspection of our sterile drug product facility in Bangalore in March 2018. The report lists 6 major observations with no observation classified as critical. We will submit a corrective and preventive action plan to the European inspection agency within the stipulated time period."

- Biocon Spokesperson

<< Back

 

 Download Company  Statement
 
 
 
 
     
  Biocon

Businesses

Recommended sites Biocon on  
  Home
About Us

Investor Relations
Media Relations
Careers
Site Map
Contact Us
Our Growth Accelerators
Fact Sheet
Branded Formulations
Biopharmaceuticals
Research Services
Active Discovery Program

ABLE
Karnataka Vision Group on BT
Syngene International
Biocon Academy

    Linked In   
       
  Report adverse event/side effects and product complaints    
       
  * Disclaimer            © 2018, Biocon. All Rights Reserved